Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Prowell, 2012, Pathological complete response and accelerated drug approval in early breast cancer, N Engl J Med, 366, 2438, 10.1056/NEJMp1205737 Bonadonna, 1993, Preoperative chemotherapy in operable breast cancer, Lancet, 341, 1485, 10.1016/0140-6736(93)90933-8 Cameron, 1997, Primary systemic therapy for operable breast cancer—10-year survival data after chemotherapy and hormone therapy, Br J Cancer, 76, 1099, 10.1038/bjc.1997.514 Liedtke, 2008, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, 26, 1275, 10.1200/JCO.2007.14.4147 Mieog, 2007, Preoperative chemotherapy for women with operable breast cancer, Cochrane Database Syst Rev, 2 Burzykowski, 2005, An ordinal surrogate for a survival true endpoint Untch, 2009, Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer, J Clin Oncol, 27, 2938, 10.1200/JCO.2008.20.3133 Gianni, 2009, Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer, J Clin Oncol, 27, 2474, 10.1200/JCO.2008.19.2567 Bonnefoi, 2011, TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial, Lancet Oncol, 12, 527, 10.1016/S1470-2045(11)70094-8 von Minckwitz, 2005, Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group, J Clin Oncol, 23, 2676, 10.1200/JCO.2005.05.078 von Minckwitz, 2010, Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study, J Clin Oncol, 28, 2015, 10.1200/JCO.2009.23.8303 Untch, 2010, Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study, J Clin Oncol, 28, 2024, 10.1200/JCO.2009.23.8451 von Minckwitz, 2008, Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial, J Natl Cancer Inst, 100, 542, 10.1093/jnci/djn085 von Minckwitz, 2008, Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study, J Natl Cancer Inst, 100, 552, 10.1093/jnci/djn089 von Minckwitz, 2005, In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study, Ann Oncol, 16, 56, 10.1093/annonc/mdi001 Gianni, 2010, Lancet, 375, 377, 10.1016/S0140-6736(09)61964-4 Wolmark, 2001, Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18, J Natl Cancer Inst Monogr, 30, 96, 10.1093/oxfordjournals.jncimonographs.a003469 Rastogi, 2008, Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol, 26, 778, 10.1200/JCO.2007.15.0235 Bear, 2003, The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol, 21, 4165, 10.1200/JCO.2003.12.005 Untch, 2011, Ann Oncol, 22, 1988, 10.1093/annonc/mdq709 Untch, 2011, Ann Oncol, 22, 1999, 10.1093/annonc/mdq713 Untch, 2011, Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, 29, 3351, 10.1200/JCO.2010.31.4930 von Minckwitz, 2011, Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, 125, 145, 10.1007/s10549-010-1228-x Feldman, 1986, Pathological assessment of response to induction chemotherapy in breast cancer, Cancer Res, 46, 2578 Mazouni, 2007, Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome, J Clin Oncol, 25, 2650, 10.1200/JCO.2006.08.2271 von Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200/JCO.2011.38.8595 Buyse, 2008, Individual- and trial-level surrogacy in colorectal cancer, Stat Methods Med Res, 17, 467, 10.1177/0962280207081864